Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

Abstract Background Pembrolizumab alone or in combination with chemotherapy is a standard treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression. However, no study has compared the efficacies of these two regimens. Therefore, we aimed to...

Full description

Bibliographic Details
Main Authors: Hiromi Matsumoto, Nobuaki Kobayashi, Kohei Somekawa, Nobuhiko Fukuda, Ayami Kaneko, Chisato Kamimaki, Sousuke Kubo, Katsushi Tanaka, Yoichi Tagami, Shuhei Teranishi, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Harumi Koizumi, Kenji Miura, Naoki Miyazawa, Takeshi Kaneko
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Thoracic Cancer
Subjects:
metastasis
non‐small‐cell lung cancer
pembrolizumab
Online Access:https://doi.org/10.1111/1759-7714.14252

Internet

https://doi.org/10.1111/1759-7714.14252

Similar Items